R42 Group

Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of biological substances such as proteins, DNA, and small molecules. The company focuses on simplifying the analysis of these biomolecules for pharmaceutical research and manufacturing. Its diagnostic analyzers and kits facilitate the analysis of biomolecular interactions, including protein interaction analysis, enabling researchers to achieve sensitive and timely medical diagnoses. Through its innovative technology, Abselion enhances the efficiency of biomedical research and contributes to advancements in medical diagnostics.

Healx, established in 2014 and headquartered in Cambridge, UK, is a biotechnology company specializing in rare disease treatments. It employs artificial intelligence and machine learning to identify and repurpose existing drugs for new therapeutic uses, aiming to accelerate drug discovery and reduce development risks. By integrating deep pharmacology expertise and patient engagement, Healx matches treatments to disease patients, addressing unmet needs in the rare disease space.

Xwatts is a developer of an intelligent energy management system specifically designed for commercial buildings. The company focuses on reducing costs and emissions through continuous analysis of energy usage patterns, environmental conditions, and market data. By optimizing and automating electricity consumption, Xwatts enables building owners to take direct control of their distributed energy assets. The system evaluates historical usage alongside real-time market data to enhance asset scheduling and minimize electricity consumption costs, thereby promoting more efficient energy management in commercial properties.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Reservoir Neuroscience, Inc. is a biopharmaceutical company focused on developing innovative therapeutics aimed at repairing the blood-brain barrier and restoring vascular function in the brain. Founded in 2019 and based in Emeryville, California, the company targets neurological disorders, including Alzheimer's disease, by addressing dysfunctional blood vessels in the brain. Its therapeutics are designed to improve cognitive function and enhance disease outcomes for patients suffering from age-related cognitive impairment and other neurological conditions.

Soopra is a platform that allows experts to create AI personas to interact with their audiences 24/7, providing a new, scalable way to monetize their knowledge.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunction in neurological diseases, particularly higher-frequency migraines and potentially Alzheimer's disease. The company is dedicated to creating a novel medical food that enhances brain energetics by providing ketone bodies as an alternative fuel source when glucose metabolism is impaired. Located in the Technologie Park Basel, KetoSwiss operates within a vibrant community of academic research and life sciences innovation, positioning itself at the forefront of preventive therapies for neurological conditions. Through rigorous clinical testing, KetoSwiss seeks to offer effective dietary solutions to improve the quality of life for patients affected by these conditions.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunction in neurological diseases, particularly higher-frequency migraines and potentially Alzheimer's disease. The company is dedicated to creating a novel medical food that enhances brain energetics by providing ketone bodies as an alternative fuel source when glucose metabolism is impaired. Located in the Technologie Park Basel, KetoSwiss operates within a vibrant community of academic research and life sciences innovation, positioning itself at the forefront of preventive therapies for neurological conditions. Through rigorous clinical testing, KetoSwiss seeks to offer effective dietary solutions to improve the quality of life for patients affected by these conditions.

Silveray is a company focused on developing affordable large-area direct conversion detectors specifically for the X-ray imaging market. It leverages advanced core technology that delivers high-performance X-ray imaging through the use of nanoparticle-based X-ray conversion materials. These materials are produced as a semiconductor ink, which is then deposited onto a pixel backplane. This innovative approach enables healthcare providers and various industries to generate an electrical current response to detected X-ray photons, all while maintaining a sustainable cost point. Silveray aims to enhance the efficiency and accessibility of X-ray imaging solutions.

WiseWorks AI is a meeting automation platform focused on improving workflows for corporate governance professionals by minimizing time spent on inefficient tasks. The company has developed a communications intelligence platform that assists financial institutions in extracting vital insights from audio and video interactions. By automating processes such as recording, transcribing, and analyzing communications, WiseWorks AI enhances operational efficiency and helps organizations mitigate risks. Their technology aims to streamline information retrieval and facilitate better decision-making within corporate environments.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Stamp Free operates as a digital postage stamp company. It provides an app that enables personal and business customers to buy stamps or digital postage directly on their mobile phones, facilitating the posting of letters or parcels in the usual manner.

Oxford Drug Design is a biotechnology company focused on developing innovative therapies to combat drug-resistant infections. The company employs advanced methodologies in computer-aided drug discovery, encompassing the entire process from target identification to preclinical studies and formulation. Its multidisciplinary research team integrates breakthroughs in computational chemistry, cheminformatics, mathematics, and cloud computing to enhance drug discovery efforts. The company's flagship platform, DrugFinder, represents a next-generation approach to identifying and developing new antibiotics, particularly targeting challenging diseases with significant unmet medical needs. By leveraging these technologies, Oxford Drug Design aims to provide healthcare professionals with effective treatment options for patients suffering from antibiotic-resistant bacterial infections.

Bounce Imaging, Inc. is a manufacturer of tactical throwable cameras equipped with multiple lenses and sensors, designed primarily for police and fire responders. The company specializes in developing omnidirectional cameras and sensor technology that allows first responders to safely monitor hazardous environments from a distance, enhancing their operational safety. Founded in 2012 and headquartered in Buffalo, New York, Bounce Imaging provides a variety of supportive accessories such as pole attachments, tethers, car chargers, headsets, wrist straps, and magnetic mounts. In addition to its hardware offerings, the company also delivers cloud services, including technical consulting, design and implementation support, and troubleshooting assistance for imaging and processing hardware. Bounce Imaging's innovative solutions enable users to capture real-time videos and sensor data consistently, even in challenging conditions, making it a valuable asset in the defense and first response sectors.

Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.

ExSeed Health offers a home sperm testing kit that assesses fertility based on sperm count and motility. The company also provides refill kits, selling its products through retail stores and online channels.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

VividQ Limited is a technology company based in Cambridge, United Kingdom, specializing in the development of software frameworks for generating, compressing, and transmitting 3D holographic images and video. The company offers a variety of products, including VividQ Capture, an API for converting 3D data into holographic formats, and VividQ Squeeze, a solution for compressing point cloud 3D data. Additionally, VividQ Core enables multi-user interactions with holograms at different focal planes, while VividQ View allows integration of various spatial light modulators into its holographic architecture. VividQ's advanced computational display technology aims to revolutionize digital displays by integrating holographic visuals into consumer electronics, augmented reality, virtual reality, and automotive applications. The company, which was formerly known as Penteract28 Limited before rebranding in 2017, collaborates with leading original equipment manufacturers to enhance user experiences in various sectors, including gaming, immersive simulations, and depth sensing.

Genomelink operates a digital genetic analysis platform that lets individuals upload their raw DNA data to generate reports on traits, wellness, ancestry, and nutrition. The service translates genomic information into user-friendly interpretations for personal exploration and genetic self-knowledge. It emphasizes data privacy by upholding user ownership of data, implementing ISO-certified security, and offering options to delete data. The company positions itself as a consumer-focused provider of accessible, detailed genomic insights, supporting informed health and lifestyle decisions while ensuring control and transparency over personal genetic information.

Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of biological substances such as proteins, DNA, and small molecules. The company focuses on simplifying the analysis of these biomolecules for pharmaceutical research and manufacturing. Its diagnostic analyzers and kits facilitate the analysis of biomolecular interactions, including protein interaction analysis, enabling researchers to achieve sensitive and timely medical diagnoses. Through its innovative technology, Abselion enhances the efficiency of biomedical research and contributes to advancements in medical diagnostics.

Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Stamp Free operates as a digital postage stamp company. It provides an app that enables personal and business customers to buy stamps or digital postage directly on their mobile phones, facilitating the posting of letters or parcels in the usual manner.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Exogene is a biotechnology company focused on advancing T-cell receptor (TCR)-based cancer immunotherapies for solid tumors. By integrating deep learning with high-throughput TCR-antigen screening, Exogene aims to efficiently identify new tumor targets that are common among cancer patients. The company is developing a computational platform designed to discover effective and safe TCRs against these targets, facilitating their therapeutic application. This innovative approach allows for the rapid and cost-effective development of TCR-based immunotherapies, ultimately supporting healthcare providers in creating cell therapies that enhance the immune system's ability to combat cancer.